Lv31
280 积分 2025-12-13 加入
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
5小时前
已完结
Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
12天前
已完结
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?
12天前
已完结
What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?
20天前
已完结
Endoscopy in inflammatory bowel disease: what every endoscopist should know
1个月前
已完结
Global consensus statement on the management of pregnancy in inflammatory bowel disease
1个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
1个月前
已完结
Magnetic resonance cell size imaging reveals intestinal fibrosis to predict intestinal disease progression in patients with Crohn’s disease
1个月前
已完结
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
1个月前
已完结
IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus
2个月前
已完结
皖公网安备34019202002308
